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Twenty-two cases of purely ocular myasthenia gravis were reviewed to 
evaluate the long-term effects of thymectomy. Remission rate increased 
gradually with time (11.8% at 3 years, 23.1% at 5 years, and 33.3% at 10 
years). Analysis of factors influencing remission with time showed that 
patients with short duration of illness attained remission significantly 
earlier (p = 0.035 at 5-year follow-up). One of 22 patients with purely 
ocular myasthenia gravis (4.5%) had disease progression. Because ocular 
myasthenia gravis often progresses to the generalized type and because 
duration of illness before operation is one of important factors influencing 
remission, we conclude that thymectomy in the earlier stages of the disease 
is the preferred treatment for ocular myasthenia gravis, just as for 
generalized myasthenia gravis. (J Thorac Cardiovasc Surg 1996;112:371-5) 
T hymectomy has been established as an effective therapeutic modality for generalized myasthenia 
gravis (MG). 1' 2 Recently, the trend has been toward 
more extensive to complete dissection of thymic 
tissues3; however, for MG of the ocular type the 
effectiveness of thymectomy remains controversial. 
Because ocular MG is not a life-threatening disease 
and may also have natural remission, thymectomy 
for ocular MG does not have as great an effect on it 
as on generalized MG. On the other hand, ocular 
MG often progresses to generalized MG and may be 
complicated by occult thymoma not detected before 
operation. 
For these reasons, we have treated ocular MG 
with thymectomy. To evaluate the effect of thymec- 
tomy and analyze the factors influencing outcome, 
we performed a retrospective r view of 22 cases of 
purely ocular MG treated with thymectomy. 
Patients and methods 
The cases of 22 consecutive patients with ocular MG 
without thymoma who underwent thymectomy atTottori 
University Hospital between January 1971 and December 
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1993 were reviewed. These were eight male and 14 female 
patients ranging in age from 9 to 60 years (mean 34.3 
years). Before operation, Grave's disease was detected in 
four patients and Hashimoto's disease was detected in one 
patient. Both thyroid diseases were diagnosed by abnor- 
mal serum levels of thyroid hormones and autoantibodies 
(anti-thyroid stimulating hormone receptor, antithyro- 
globulin, and antimicrosomal ntibodies). All patients 
were initially evaluated by neurologists and determined to
have ocular MG (fluctuating weakness of ocular muscles 
only) by neurologic examination. A positive result of 
edrophonium testing and waning phenomenon of only 
orbicularis oculi muscle on electromyography were the 
most important findings for all patients in the diagnosis of 
ocular MG. Serum titers of anti-acetylcholine r ceptor 
antibody (anti-AchR Ab) were measured in 18 of the 22 
patients by immunoprecipitation iodine 125-labeled 
c~-bungarotoxin-acetylcholine rec ptor complex (normal 
level is less than 0.16 pmol/ml). Greater than normal 
levels of anti-AchR Ab were not always necessary for 
diagnosis of ocular MG. 
For preoperative treatment, a ticholinesterase agents 
(distigmine bromide or pyridostigmine bromide) were 
used in 16 cases, steroids were used in three cases, and 
nothing was used in three cases (Table I). The operative 
procedures were performed through the transsternal 
route. Simple thymectomy was performed in four cases 
before 1980; extended thymectomy, accompanied by total 
removal of the anterior mediastinal dipose tissue, which 
includes thymus tissues, was performed in 18 cases after 
1981. This was established as a standard method. After the 
operation, in which steroid treatments were started for all 
patients in the early postoperative period, with pulsed 
therapy at the beginning and gradually decreasing drug 
doses later. Postoperative assessment of the effects of 
thymectomy on ocular MG was conducted at 3 months, 6 
months, and 1, 2, 3, 4, 5, 7, and 10 years after operation. 
Mean follow-up time for all patients was 69.1 months. The 
classification system used to grade clinical improvement is 
371 
3 7 2 Nakamura et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
August 1996 
~)  
100-  
80  
60 
40 
20"  
0 
r L / !~i!i!-!:i! 
!:!:i-*!:::i / : - : " - " : :  . . . . . .  :i."~!~,'~i" . . . . .  ~ i ! ,  / / /  
• .'.','.',' - ......... " " " " / / i  
:.:.:.:.:.: -!-.:-;.:--:.: : : : : . . .  .:.:.:...:. ~ /  - -  
. . . .  . . . . / / /  
.; .; .:,;,:,  " " " " I I I  
. . . . . . . . . . . . . .  I I / . "  
:!:i:i:i:i: . . . .  : : : : :~:!:-.~: : :  : : : : : : .... / 
/ I  - I I I I -  Im"  
3 6 12  24  36  48  
Fo l low-up  (months)  
Remiss ions  (%) 4 5 4 5 
No. of  Pat ients  22 22 
No. of  Pat ients  
1 1 
in Remiss ion  
I 
i ! 
[ 
6O 84  1 20  
4,5  10o0 11 ,8  13°3  23°1 36 ,4  33 ,3  
22 20 17 15 13 11 6 
1 2 2 2 3 4 2 
Fig. 1. The effects with time of 22 thymectomies for purely ocular MG. 
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Table I. Preoperative medications in ocular MG Table III. Results of thymectomy for ocular MG 
Medication No. of cases Remission 
Anticholinesterase gents (distigmine 16 No. % 
bromide or pyridostigmine bromide) 
Steroids 3 Total 5/22 22.7 
Nothing 3 Age (yr) 
-<39 4/17 23.5 
->40 1/5 20.0 
Age of onset (yr) 
Table II. Classification of postoperative r sponses -<34 4/15 26.7 
->35 1/7 14.3 
in ocular MG Duration of illness (too) 
Medication -<12 3/8 37.5 
Response Symptoms required ->13 2/14 14.3 
Remission None None Sex 
Improvement Improved Decreased Male 2/8 25.0 
Improved Unchanged Female 3/14 21.4 
Unchanged Decreased Operative procedure 
No change Unchanged Unchanged Extended thymectomy 4/18 22.2 
Improved Increased Thymectomy 1/4 25.0 
Worse Worse Increased Germinal center 
Worse Unchanged Positive 4/14 28.6 
Unchanged Increased Negative 1/8 12.5 
Death Anti-AchR Ab 
Positive 2/8 25.0 
Negative 2/10 20.0 
shown in Table II. Remission was defined as complete 
freedom from symptoms without medication for longer 
than 3 months. Pathologic studies were performed by 
rereading the actual slide for this study, and hyperplasia of
germinal center of thymic tissue was carefully examined. 
The X= test or Fisher's Exact Test and the Kruskal- 
Wallis nonparametric method were used for statistical 
analysis of differences. A p value of less than 0.05 was 
considered statistically significant. 
Remission was evaluated at the last observation point in each case. 
Results 
For purely ocular MG without thymoma, remis- 
sion rate was 22.7% at the last observation point. 
Analysis of factors influencing remission at the last 
observation point showed no statistically significant 
differences between all pairs of groups by age, age of 
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Fig. 2. Remission rate after thymectomy for purely ocular MG over time according to age (A), age of onset 
(B), duration of illness before thymectomy (C), sex (I)), operative procedure (E), germinal center (GC, F), 
and anti-AchR Ab ((3). At the 5-year follow up interval, patients with duration of illness of 12 months or 
less had significantly better remission than those with durations of 13 months or more (p = 0.035 by 
Fisher's Exact Test). 
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Fig. 3. Relationship between remission and duration of illness before thymectomy in all 22 patients with 
ocular MG. Patients with shorter duration of illness had a tendency toward earlier remission. OP, 
Operation; A, onset of disease; II, operation; O, remission; x, no remission. 
Table IV. Remission rate related to MG classification and the duration of illness 
Duration of 
MG classification Cases illness (mo) 10 years 
Remission rate (%) 
Last observation 
I (Ocular) 22 71.1 33.3 22.7 
IIa (Mild general) 26 45.4 50.0 30.8 
lib (Severe general) 16 47.6 40.0 37.5 
Ocular MG showed a tendency toward longer durations of illness and worse remission rates than seen in the other two groups. 
onset, duration of illness, sex, operative procedure, 
hyperplasia of germinal center, and anti-AchR Ab 
(Table III). When the postoperative time course was 
studied, remission rates were seen to increase grad- 
ually with time (4.5% at 1 year, 11.8% at 3 years, 
23.1% at 5 years, 33.3% at 10 years; Fig. 1). Analysis 
of factors influencing remission showed that dura- 
tion of illness before operation was an important 
factor in the postoperative time course study. Cases 
in which the duration of illness before operation was 
less than 12 months showed significant earlier and 
better remission than those with duration longer 
than 12 months before operation (p = 0.035 at 
5-year follow-up; Figs. 2 and 3). 
Disease progression of purely ocular MG oc- 
curred in one of 22 patients (4.5%), a 34-year-old 
woman whose disease progressed to the generalized 
type of MG shortly after operation. There was no 
morbidity associated with the surgical procedure 
and no deaths occurred uring hospitalization. 
Results from patients with ocular MG were com- 
pared with those of patients with the other types of 
MG without thymoma who underwent operation 
during the same period. Patients with ocular MG 
had the longest durations of illness before operation 
and worst remission rates of the three groups (Table 
IV). There were, however, no statistically significant 
differences. 
Discussion 
Ocular MG is defined as a disease with only 
ocular symptoms and without abnormal general 
findings even on electromyography. An important 
question is whether ocular symptoms are the initial 
symptoms of generalized MG. Bever and col- 
leagues 4 reported that 43 (36%) of 119 cases of 
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ocular MG progressed to the generalized type of 
MG within 2 years. In our study, only one of 22 
patients (4.5%) had disease progression to general- 
ized MG, a particularly favorable result compared 
with the previous tudy. It is still difficult, however, 
to anticipate which cases will progress to generalized 
MG. In the therapy of ocular MG, Fisher and 
Schwartmann 5 reported that treatment with steroids 
alone was associated with relapse and that surgical 
treatments were indicated as for generalized MG. 
On the other hand, Oosterhuis 6 reported that about 
30% of cases of ocular MG underwent natural 
remission during the course of 15 years. These 
results caused confusion in devising a strategy for 
treatment of ocular MG. 
Little published literature about the long-term 
results of thymectomy for ocular MG is available 
because of the small number of cases. Even in the 
large series of 2062 cases of all types of MG 
reported on by Papatestas and coworkers, 7 thymec- 
tomy was performed in only 12 (3.8%) of 313 cases 
of ocular MG. In their report, they showed that 
remission occurred in 59 (20%) of 301 patients who 
did not undergo thymectomy and in two (17%) of 12 
patients who underwent thymectomy. These results 
suggested that it would not be helpful to perform 
surgical procedure in cases of ocular MG. Schumm 
and colleagues 8 howed the effectiveness of thymec- 
tomy for ocular MG, however, with a palliation rate 
of almost 80% and remission occurring in three 
(16.7%) of 18 patients during a mean follow-up of 
only 26 months. 
In the analysis of factors influencing remission of 
generalized MG, Papatestas and coworkers 7 showed 
that severity of disease, presence of thymoma, du- 
ration of illness, and surgical method affected out- 
come, whereas First and associates 9 demonstrated 
by multiple-regression a alysis that age, sex, and 
preoperative stage were significant factors. Monden 
and coworkers, 1° who found duration of illness 
before operation to be a significant factor in the 
outcome of generalized MG, showed a correlation 
between duration of illness before operation and 
thymic hyperplasia of the germinal center on his- 
topathologic examination. In the future, indexes 
concerned with the progression of ocular to gener- 
alized MG may include factors such as duration of 
illness, thymic hyperplasia of the germinal center, 
and anti-AchR Ab titer. 
Our study showed an effectiveness for thymec- 
tomy in the treatment purely ocular MG just as in 
the treatment of generalized MG, especially for 
protection against progression to generalized MG. 
It is also important hat there is little risk in per- 
forming the surgical procedure and managing the 
perioperative period versus generalized MG. Some 
of these patients, however, might have had natural 
remission later without thymectomy. If the factors 
affecting progression to generalized MG can be 
defined, it will be possible to select patients to 
undergo thymectomy, but for now because one of 
important factors influencing remission of ocular 
MG is the duration of illness before thymectomy, we 
recommend thymectomy in the early stages of the 
disease as the preferred treatment in ocular MG, 
just as in generalized MG. 
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